Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2003

View Archived Issues

Adefovir dipivoxil in chronic hepatitis B

Beneficial effects described for bortezomib in patients with relapsed, refractory myeloma

Potential new molecularly targeted therapies for diseases related to activated PDGFR-alpha

Reduced toxicity and improved antitumor effects for IL-2 when coadministered with M-40403

MDX-010 combined with tumor vaccines in metastatic melanoma

Nonuterotrophic and nonmammotrophic ERbeta ligands presented by Wyeth

Novel PTP1B inhibitors prepared and tested by JT researchers

Pharmasset patent covers new anti-HIV and anti-HBV agents

Series of potassium channel modulators and their use reported by Wyeth

Pfizer researchers present new antidiarrheal agents in recent patent

New telomerase inhibitors under study at Kyowa Hakko

New antiproliferative agents in Sankyo development pipeline

Cytotoxic macrolactones discovered at GBF assumed to act by inhibiting V-ATPase

JNJ-10258859: a novel PDE5 inhibitor with potential in erectile dysfunction

Erectile responses to DA-8159 in rabbit models

Promising activity reported for Nipent combination therapy in NHL

Parenteral anti-MRSA cephalosporin antibiotic characterized by Takeda

Enrollment completed for phase I/II study of 131I-TM-601 in glioma

Theratechnologies completes patient enrollment in phase II ThGRF study

China approves Sumitomo's antianxiety drug Sediel

Daiichi Radioisotope files for marketing approval of Dopascan Injection in Japan

Ivax initiates phase II trial of talampanel for brain cancer

Schering announces positive phase III results for MS-325

BMS presents second-generation farnesyltransferase inhibitors at AACR meeting

Optimization of CDK-2 inhibitor series as orally active antitumor agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...